Gene therapy for hemophilia represents a groundbreaking advance in the landscape of hemophilia treatment, offering new hope to patients like Terence Blue, who recently became the first to receive this innovative therapy in New England.Hemgenix therapy, approved by the FDA in November 2022, aims to significantly alter the lives of those affected by hemophilia B by reducing reliance on daily infusions of clotting factor.